| Name | Cvs Pharmacy #06283 |
|---|---|
| Organization Name | Virginia Cvs Pharmacy Llc |
| Location | 817 W Main St, Danville, Virginia 24541 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (434) 793-0231 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.
A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.
EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.
› Verified 4 days ago
| NPI Number | 1356444087 |
| Organization Name | VIRGINIA CVS PHARMACY LLC |
| Doing Business As | CVS PHARMACY #06283 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 817 W Main St, Danville, VA 24541 |
| Phone Number | 434-793-0231 |
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.
A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.
EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.
› Verified 4 days ago
News Archive
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.
A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.
EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.
› Verified 4 days ago
Commonwealth Home Health Care Type: DME Supplier - Oxygen Equipment & Supplies Location: 479 Piney Forest Rd, Danville, Virginia 24540 Phone: (434) 797-2332 | |
Commonwealth Orthotics And Prosthet Type: Prosthetic/Orthotic Supplier Location: 413 Mount Cross Road, Danville, Virginia 24541 Phone: (434) 836-4736 | |
Excel Prosthetics & Orthotics, Inc. Type: Durable Medical Equipment & Medical Supplies Supplier Location: 312 S Main St, Danville, Virginia 24541 Phone: (434) 797-1191 | |
Family Eyecare Center Type: Medicare Supplier Location: 415 Piney Forest Rd, Danville, Virginia 24540 Phone: (434) 793-2020 | |
Freedom Respiratory Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1155 Piney Forest Rd, Danville, Virginia 24540 Phone: (434) 836-6996 |